Aptevo Therapeutics Inc. (Nasdaq: APVO), a clinical-stage biotechnology company, reported its financial results for the quarter ended June 30, 2025. The company experienced a net loss of $6.2 million for the quarter, compared to a net loss of $5.9 million in the same period in 2024. In terms of expenses, research and development costs decreased by $0.3 million, from $3.6 million in Q2 2024 to $3.3 million in Q2 2025, mainly due to reduced preclinical and ALG.APV-527 spending. However, general and administrative expenses rose by $0.5 million, from $2.4 million to $2.9 million, primarily due to higher consulting costs. During the quarter, Aptevo raised $15.9 million in gross proceeds from various equity offerings, increasing its cash position to $9.4 million as of June 30, 2025. The company also secured an equity line of credit for up to an additional $25 million in capital, which extends its cash runway into late Q4 2025. Significant updates in Aptevo's business operations include the introduction of APVO455, a Nectin-4 x CD3 bispecific for solid tumors, expanding its portfolio of CRIS-7-derived CD3 engaging molecules. The company's lead candidate, mipletamig, achieved an 85% remission rate in frontline acute myeloid leukemia $(AML.AU)$ patients across two trials in combination therapy. This expansion underscores Aptevo's commitment to advancing next-generation immunotherapies in areas of significant unmet need.